Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Benign prostatic hyperplasia and its treatment: Impact on quality of life and se...
Journal Information
Vol. 37. Issue 4.
Pages 233-241 (April 2013)
Share
Share
Download PDF
More article options
ePub
Visits
987
Vol. 37. Issue 4.
Pages 233-241 (April 2013)
Original article
Benign prostatic hyperplasia and its treatment: Impact on quality of life and sexual function
Hiperplasia benigna de próstata y su tratamiento: impacto en calidad de vida y función sexual
Visits
...
D. Castro-Díaza, H. Díaz-Cuervob,��
Corresponding author
helena@baphealth.com

Corresponding author.
, M. Pérezc
a Servicio de Urología, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
b BAP Health Outcomes Research S.L, Oviedo, Spain
c Departamento Médico, Almirall S.A., Barcelona, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (4)
Table 1. Description of the sample in terms of sociodemographic and clinical variables.
Table 2. Scores in the questionnaires.
Table 3. Differences by age groups in the items relating to the impact of problems in ejaculation.
Table 4. Regression models for the prediction of the scores of the questionnaires.
Show moreShow less
Abstract
Objectives

To evaluate the impact of benign prostatic hyperplasia (BPH) on health related quality of life (HRQoL) and sexual function, in patients with moderate–severe lower tract urinary symptoms (LUTS/BPH) under treatment with alpha-blockers; to study differences associated to age, urinary symptom severity and time under treatment.

Materials and methods

1580 patients diagnosed of BPH and LUTS/BPH, and in treatment with alpha-blockers were recruited in urology practices all around Spain. Socio-demographic- and clinic-data together with LUTS/HBP severity assessment (IPSS questionnaire) and responses to EQ-5D and the Sexual Function Index Questionnaire (SFI) were collected. A descriptive statistical analysis was performed, as well as test to contrast the results by age, LUTS/HBP severity and time under treatment; multiple linear regression models were adjusted for the answers to EQ-5D and SFI.

Results

Analysis database contained information of 1514 patients. Mean age (SD) was 63 (5.5) years (26.75% under 60 years), mean treatment time 1.8 (2.09) years (51.19% under one year). Mean questionnaire scores were: IPSS 17.29 (5.66) (65.85% moderate symptoms), EQ-5D 90 (14). The SFI-domains with worse scores were satisfaction and sexual drive. 52.58% of patients presented deteriorated HRQoL (IPSS-item 8). Age, symptom severity and time under treatment showed association with HRQoL and sexual function.

Conclusions

BPH and its treatment impact negatively on HRQOL and sexual function, with a more pronounced deterioration in patients with severe LUTS/HBP, in older patients and in patients in treatment over a year.

Keywords:
Health related quality of life
Sexual function
Erectile dysfunction
Benign prostate hyperplasia
Low urinary tract symptoms
Treatment
Resumen
Objetivos

Evaluar el impacto en la Calidad de Vida Relacionada con la Salud (CVRS) y en la función sexual de la Hiperplasia Benigna de Próstata (HBP) y su tratamiento, en pacientes con síntomas urinarios (STUI/HBP) moderados-graves en tratamiento con alfa-bloqueantes; estudiar las diferencias asociadas a edad, gravedad de síntomas urinarios y tiempo con tratamiento.

Material y métodos

Se reclutaron 1.580 pacientes diagnosticados de HBP y con STUI/HBP en tratamiento con alfa-bloqueantes, en consultas de urología de toda España. Se recogieron datos socio-demográficos, clínicos y de gravedad de STUI/HBP (cuestionario IPSS) y las respuestas al cuestionario EQ-5D y el “Sexual Function Index-SFI”. Se realizó un análisis estadístico descriptivo, contrastes por edad, gravedad de STUI/HBP y tiempo de tratamiento y se ajustaron modelos lineales de regresión múltiple para las respuestas al EQ-5D y SFI.

Resultados

Se analizaron datos de 1.514 pacientes. La media (D.E) de edad fue 63 (5,5) años (26,75%<60 años), de tiempo de tratamiento 1,8 (2,0) años (51,19%<1 año), para IPSS 17,29 (5,66) puntos (65,85% síntomas moderados), para EQ-5D 90 (14) puntos. Las dimensiones del SFI más dañadas fueron satisfacción y deseo. El 52,58% de los pacientes mostraron afectación en CVRS (IPSS-ítem 8). Edad, gravedad de síntomas y tiempo en tratamiento mostraron asociación con CVRS y función sexual.

Conclusiones

La HBP y su tratamiento impactan negativamente en la CVRS y en la función sexual, siendo el deterioro mayor en pacientes con síntomas STU/HBP graves, en los de mayor edad y en los que llevaban más de 1 año de tratamiento.

Palabras clave:
Calidad de vida relacionada con la salud
Función sexual
Disfunción eréctil
Hiperplasia benigna de próstata
Síntomas del tracto urinario inferior
Tratamiento

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos